Physician profile
Amber Bellamy
NPI 1144481755
$688.02
in general payments reported to CMS, 2019-2025
15 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.19 · 2024: $244 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $159.68 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $108.15 | 2024-2025 | Repatha, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $69.28 | 2024-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $52.86 | 2025 | Gardasil 9, Capvaxive |
| Novo Nordisk INC | $48.35 | 2024-2025 | Wegovy, Ozempic |
| Sanofi-Aventis U.S. LLC | $46.27 | 2025 | |
| Abbvie INC. | $34.81 | 2024-2025 | |
| Pfizer INC. | $33.13 | 2024-2025 | |
| Astellas Pharma US INC | $27.72 | 2023 | Veozah |
| Lilly USA, LLC | $21.23 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $20.40 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $17.40 | 2025 | Pico 14, "Acticoat 4"" X 4""", Pico 7 |
| Currax Pharmaceuticals LLC | $16.47 | 2023 | Onzetra Xsail, Contrave |
| Sanofi Pasteur INC. | $16.43 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.84 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Bellamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.